Mesenchymal Stem Cell-Based Therapies against Podocyte Damage in Diabetic Nephropathy.
10.1007/s13770-017-0026-5
- Author:
Manizheh KHALILPOURFARSHBAFI
1
;
Fatemeh HAJIAGHAALIPOUR
;
Kesavanarayanan KRISHNAN SELVARAJAN
;
Aishah ADAM
Author Information
1. Faculty of Pharmacy, Universiti Teknologi MARA (UiTM), 42300 Bandar Puncak Alam, Selangor Darul Ehsan, Malaysia. drkskesavan@gmail.com
- Publication Type:Review
- Keywords:
Mesenchymal stem cells;
Podocyte damage;
Diabetic nephropathy;
Kidney ultrafiltration;
Glomerular function
- MeSH:
Adult Stem Cells;
Apoptosis;
Diabetic Nephropathies*;
Hope;
Intercellular Signaling Peptides and Proteins;
Kidney;
Kidney Diseases;
Kidney Failure, Chronic;
Mesenchymal Stromal Cells;
Podocytes*;
Proteinuria;
Regeneration;
Ultrafiltration
- From:
Tissue Engineering and Regenerative Medicine
2017;14(3):201-210
- CountryRepublic of Korea
- Language:English
-
Abstract:
Injury to podocytes is an early event in diabetic nephropathy leading to proteinuria with possible progression to end-stage renal failure. The podocytes are unique and highly specialized cells that cover the outer layer of kidney ultrafiltration barrier and play an important role in glomerular function. In the past few decades, adult stem cells, such as mesenchymal stem cells (MSCs) with a regenerative and differentiative capacity have been extensively used in cell-based therapies. In addition to their capability for regeneration and differentiation, MSCs contributes to their milieu by paracrine action of a series of growth factors via antiapoptotic, mitogenic and other cytokine actions that actively participate in treatment of podocyte damage through prevention of podocyte effacement, detachment and apoptosis. It is hoped that novel stem cell-based therapies will be developed in the future to prevent podocyte injury, thereby reducing the burden of kidney disease.
